Results 121 to 130 of about 4,832 (178)

Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy. [PDF]

Front Immunol
Ou W, Wang Y, Hou C, Hou S, Zhou Y, Wang J, Wang Q.   +6 more
europepmc   +1 more source

Integrated molecular networks reveal latent components distinguishing type 2-high and type 2-low asthma. [PDF]

BMJ Open Respir Res
Ramirez M, Diaz MP, Wang N, Liu Q, Li H, Kay S, Shuguli M, Zielonka J, Wilson G, Sauler M, Wang Z, Yan X, Chupp G, Gomez JL.   +13 more
europepmc   +1 more source

Biologics in Chronic Obstructive Pulmonary Disease: Current Status and Future Prospects. [PDF]

Tuberc Respir Dis (Seoul)
Choi JY.
europepmc   +1 more source

Efficacy of Biological and Steroid Therapies in Adolescent and Adult Patients With Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis With Meta-Regression. [PDF]

Clin Gastroenterol Hepatol
Al Hayek M, Lucendo AJ, Savarino EV, Barberio B, Gyawali CP, Chan WW, Visaggi P, Najah Q, Yadlapati R, McCoul ED, Elhadi M, Laine L.   +11 more
europepmc   +1 more source

Feasibility of a 50% Dosing Interval Extension of Anti-IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study. [PDF]

J Asthma Allergy
Vergles M, Salai G, Tudorić N, Kovačević I, Kifer D, Lalić K, Gomerčić Palčić M, Vukić Dugac A.   +7 more
europepmc   +1 more source

Successful Treatment of Steroid-Dependent Severe Eosinophilic Pneumonia With Benralizumab: A Case Report. [PDF]

Respirol Case Rep
Ichikawa T, Takigawa Y, Fujiwara K, Inoue T, Matsumoto S, Shiraha K, Goda M, Matsuoka S, Watanabe H, Kudo K, Sato A, Sato K, Shibayama T.   +12 more
europepmc   +1 more source

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. [PDF]

Arthritis Rheumatol
Nair PK, Hellmich B, Bourdin A, Jayne DRW, Roufosse F, Khalidi N, Börjesson Sjö L, Fan Y, McCrae C, Necander S, Rodríguez-Suárez E, Shavit A, Walton C, Merkel PA, Wechsler ME.   +14 more
europepmc   +1 more source

B cell activating factor (BAFF) levels are associated with failed remission after 12 months of treatment with benralizumab and mepolizumab in severe asthma. [PDF]

Respir Res
Fischer BC, Drick N, Liu B, Riemann L, Habener A, DeLuca D, Dittrich AM, Hoeper MM, Suhling H, Hansen G, Grychtol R.   +10 more
europepmc   +1 more source

Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review. [PDF]

Front Med (Lausanne)
Alzayed A.
europepmc   +1 more source